Pemetrexed Injection, Solution, Concentrate
Product Images NDC 0409-0021

This appears to be a chart showing the survival probability of two chemotherapy treatments, PC and GC, for patients at different time intervals. The X-axis shows the survival time in months and the Y-axis shows the survival probability. The chart also includes patients at risk for each treatment at the given time intervals.*

This appears to be a chart comparing two treatments for cancer, Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC), in terms of survival probability over a certain period of time (in months). The numbers in the chart likely represent the percentage of patients who survived after a certain number of months on each treatment. However, without more context or a clear explanation of the data, it is difficult to ascertain the exact meaning of the numbers presented.*

This is a chart depicting the survival time (in months) of patients with cancer. The chart compares two treatments: Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). It shows the number of patients at risk during the treatment period, which is indicated on the bottom row (in months).*

This appears to be a chart or graph showing survival probabilities based on survival time in months. The left column lists the survival time in months, with values ranging from 2 months to 179 months. The right column lists the survival probability, with values ranging from 7% to 93%. The purpose and context of the chart is not available, but it may be related to medical research or clinical trials.*

The text shows a table displaying survival probability and survival time (in months) of patients receiving Pemetrexed and Pacebo. It also shows the number of patients at risk during each interval.*

This is a chart showing the survival probability and survival time (in months). There are six data points indicating the probabilities at different time intervals (24 months, 15 months, 12 months, 18 months, 12 months, and 9 months). This data may be useful for analyzing the success rate of a particular treatment or therapy.*

This is a table showing the survival probability of patients treated with Pemetrexed and Cisplatin (PC). The table shows the number of patients at risk (228 initially, decreasing with time) and their survival time in months. The second column lists the number of patients treated with Cisplatin and their survival time in months.*

This is a prescription drug for intravenous infusion after dilution, provided in a single-dose vial. It contains 100 mg/4 mL (25 mg/mL) of Pemetrexed Injection, and any unused portion must be discarded. It is stored refrigerated at 2°C to 8°C, and it is considered a hazardous drug. The recommended dosage must be seen in the prescribing information. The distributor is Hospira, Inc. located in Lake Forest, IL, USA. LOT and EXP numbers are available; however, their values are not present.*

This appears to be a label of a medication called "Pemetrexed" manufactured by Zydus Hospira Oncology Private Limited. It is a liquid that is stored refrigerated and needs to be diluted with 0.9% Sodium Chloride Injection before intravenous infusion. Each mL contains 25 mg of the drug and the total volume after dilution should be 100 mL. The label gives instructions on dosage, dilution, storage, and manufacturer details.*

This description is for a Pemetrexed Injection packaged in a Single Dose Vial with a strength of 500 mg/20 mL (25 mg/m). The drug is for intravenous infusion after dilution, refrigerated storage is suggested at 2°C to 8°C (36°F to 46°F). It also contains a warning that the drug is hazardous. There are several lines of text that are not readable, and no meaningful information can be obtained from them.*

The text seems to be a drug description for Pemetrexed injection for intravenous infusion after dilution. It contains the dosages recommendations, instructions for dilution, and information on how to store and administer the drug. The drug should be used within 24 hours of dilution and the unused portion should be discarded. The text also mentions that Pemetrexed contains 25 mg pemstrred, which is equivalent to 5757 g pemetrased disodium. It may contain Sodium hydroxide for pH Gustment, and no preservatives.*

This is a description for Pemetrexed Injection, which is a sterile hazardous drug recommended for intravenous infusion after dilution. It is provided in a single-dose vial of 40 mL (25mg/mL). Monothioglycerol, water for injection, and sodium hydroxide for pH adjustment are the components. Dilution has to be made with preservative-free 0.9% sodium chloride injection, USP to obtain 100 mL total volume. It is stored refrigerated at 2°C to 8°C (36°F to 46°F) and should be discarded if unused. This drug does not have a preservative, and diluted Pemetrexed Injection should be stored under refrigeration for no more than 24 hours after dilution. The recommended dosage details can be found in the prescribing information. The product is distributed by Hospira, Inc., Lake Forest, IL 60045 USA novaplus. The lot number and expiration information are listed, NDC code is0409-0004-04.*

This text seems to be a warning label or information sheet for a medication called "Pemetrexed." It contains instructions for proper storage, dilution, and administration of the drug, as well as a warning about its hazards. The medication comes in a single-dose vial and must be refrigerated at a specific temperature range. The diluted solution should be used within 24 hours and unused portions should be discarded. There is also a recommended dosage, but no further information is available.*